Unconventional AI Secures $475M Seed Funding, Hits $4.5B Valuation in Two Months
Meta description: Neuromorphic computing startup Unconventional AI raises $475 million in seed funding, reaching a $4.5 billion valuation within two […]
SanegeneBio Raises $110M in Series B to Advance RNAi Drug Pipeline
Meta description: SanegeneBio secures over $110M in Series B funding from major investors to expand RNAi drug development for multiple
Swissmedic Announces Therapeutic Expansion for Blenrep®: Key Updates for Regulatory Teams
On December 13, 2025, Swissmedic announced the extension of the therapeutic indication for Blenrep®, signaling a significant development in its
FDA Grants Approval to Avance Nerve Scaffold for Treating Sensory Nerve Discontinuity
The U.S. Food and Drug Administration (FDA) has approved Avance (acellular nerve allograft-arwx), a novel nerve scaffold, for surgical implantation
FDA Grants Regulatory Approval for Cellular Therapy to Address Severe Aplastic Anemia
The U.S. Food and Drug Administration (FDA) has taken a landmark step by granting approval for Omisirge (omidubicel-onlv), a hematopoietic
FDA Approves Augmentin XR under New Voucher Program to Boost Antibiotic Production
The U.S. Food and Drug Administration (FDA) has announced the first approval under the Commissioner’s National Priority Voucher (CNPV) pilot
FDA Grants Historic Approval to Gene Therapy for Wiskott-Aldrich Syndrome
The U.S. Food and Drug Administration (FDA) has approved Waskyra (etuvetidigene autotemcel), marking a significant milestone as the first cell-based
FDA Moves to Include Bemotrizinol in Sunscreen Formulations: A Regulatory Update
The U.S. Food and Drug Administration (FDA) announced a major step forward in sunscreen product development on December 13, 2025.
FDA Authorizes Two New Oral Treatments for Gonorrhea, Marking a Regulatory Milestone
The U.S. Food and Drug Administration (FDA) has approved two novel oral therapies for gonorrhea, a significant milestone in addressing
Urgent Recall: Hameln Pharma Ltd Issues Safety Notice for Clarithromycin 500mg Infusion Powder
Hameln Pharma Ltd has issued a Class 2 Medicines recall for specific batches of Clarithromycin 500 mg powder for concentrate